• Users Online: 1582
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO THE EDITOR
Year : 2021  |  Volume : 4  |  Issue : 4  |  Page : 791-792

Kapoor's reply to Ventrapati and Gheware et al.


Department of Medical Oncology, Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, Uttar Pradesh, India

Date of Submission14-Nov-2021
Date of Decision23-Nov-2021
Date of Acceptance27-Nov-2021
Date of Web Publication29-Dec-2021

Correspondence Address:
Akhil Kapoor
Department of Medical Oncology, Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/crst.crst_287_21

Get Permissions


How to cite this article:
Kapoor A. Kapoor's reply to Ventrapati and Gheware et al. Cancer Res Stat Treat 2021;4:791-2

How to cite this URL:
Kapoor A. Kapoor's reply to Ventrapati and Gheware et al. Cancer Res Stat Treat [serial online] 2021 [cited 2022 Jan 21];4:791-2. Available from: https://www.crstonline.com/text.asp?2021/4/4/791/334223



We thank Ventrapati and Gheware et al. for reading our article with interest and providing their comments on the same.[1],[2],[3] We agree with Ventrapati's comments that the discovery of sotorasib has paved the way to drug the undruggable.[1] We also agree that, as expected, the cost of sotorasib is very high, making it currently unaffordable for most of the patients. However, we would like to highlight the situation of trastuzumab for treating advanced breast cancer with HER2 mutation. Trastuzumab was very costly and out of reach for most of the patients from low- and middle-income countries (LMICs) when it first came into the market.[4] However, the situation gradually changed, and with the advent of multiple generics, it is now within reach of most of our patients.[5],[6] The availability of sotorasib for compassionate use in LMICs is necessary to rescue patients with KRAS G12C mutation. This will ensure that patients who need this drug the most but are unable to purchase it due to financial issues are able to get it.

We also agree with Gheware et al. that we are just at the beginning of a long road which can lead to the eradication of KRAS-mutant cancers, and it will certainly take a lot of time and efforts for the same. “Miles to go before we sleep!”

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Ventrapati P. Old targets, new bullets, nursing fresh hope. Cancer Res Stat Treat 2021;4:788-9.  Back to cited text no. 1
  [Full text]  
2.
Gheware AP, Rathor A, Jain D. From bench to bedside and beyond: Challenges in direct KRAS targeting. Cancer Res Stat Treat 2021;4:789-90.  Back to cited text no. 2
  [Full text]  
3.
Agrawal AK, Pragya R, Choudhary A, Gupta A, Sambasivaiah K, Mishra BK, et al. Sotorasib – An inhibitor of KRAS p.G12c mutation in advanced non-small cell carcinoma: A narrative drug review. Cancer Res Stat Treat 2021;4:524-8.  Back to cited text no. 3
  [Full text]  
4.
Radhakrishnan V. Drug pricing: A major barrier to access to cancer care in India. Cancer Res Stat Treat 2021;4:195-7.  Back to cited text no. 4
  [Full text]  
5.
Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007;25:625-33.  Back to cited text no. 5
    
6.
Akram Hussain SM. Molecular-based screening and therapeutics of breast and ovarian cancer in low- and middle-income countries. Cancer Res Stat Treat 2020;3:81-4.  Back to cited text no. 6
  [Full text]  




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed119    
    Printed14    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal